Literature DB >> 6575398

Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia.

C M Gomez, D P Richman.   

Abstract

Of seven rat monoclonal antibodies directed against nicotinic acetylcholine receptor, the three whose binding was blocked by alpha-bungarotoxin produced acute paralysis in chicken hatchlings, whereas the four others had no effect. In the affected animals, weakness and decremental electromyographic responses appeared within 1 hr after intravenous injection and both abnormalities improved after anticholinesterase administration. No histological changes were seen in the muscle of injected animals. These data suggest that antibodies binding in relationship to the cholinergic binding site, and presumably producing pharmacologic blockade of acetylcholine receptor, may play an important role in the pathogenesis of the defective neuromuscular transmission in myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6575398      PMCID: PMC394206          DOI: 10.1073/pnas.80.13.4089

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis.

Authors:  W L NASTUK; A J STRAUSS; K E OSSERMAN
Journal:  Am J Med       Date:  1959-03       Impact factor: 4.965

2.  Characterization of Torpedo californica acetylcholine receptor: its subunit composition and ligand-binding properties.

Authors:  M A Raftery; R L Vandlen; K L Reed; T Lee
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1976

3.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

Review 4.  Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model.

Authors:  J Lindstrom
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

5.  Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera.

Authors:  S Heinemann; J Merlie; J Lindstrom
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

6.  Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture.

Authors:  S Bevan; R W Kullberg; S F Heinemann
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

7.  Myasthenia induced by monoclonal anti-acetylcholine receptor antibodies: clinical and electrophysiological aspects.

Authors:  S A Burres; J W Crayton; C M Gomez; D P Richman
Journal:  Ann Neurol       Date:  1981-06       Impact factor: 10.422

8.  Acetylcholine receptor antibody in myasthenia gravis: purification and characterization.

Authors:  A K Lefvert; K Bergström
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

9.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

10.  Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  28 in total

1.  Rearrangement of nicotinic receptor alpha subunits during formation of the ligand binding sites.

Authors:  M Mitra; C P Wanamaker; W N Green
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

Review 2.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 4.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 5.  Specificities of autoantibodies in autoimmune receptor diseases.

Authors:  M H De Baets
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

6.  Immunochemical and pharmacological distinctions between curaremimetic neurotoxin binding sites of central, autonomic, and peripheral origin.

Authors:  R J Lukas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 7.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

8.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

9.  Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.

Authors:  C M Gomez; R L Wollmann; D P Richman
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

10.  Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.

Authors:  B Vernet-der Garabedian; J F Bach; E Morel
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.